FMW Media's New to The Street announces its feature lineup for its
business show airing on the FOX Business Network on Monday,
November 27, 2023, at 10:30 PM PT.
New to The Street's TV episode 533 will air
the following five (5) business interviews:
1). Biopharmaceutical - Acurx
Pharmaceuticals, Inc.'s (NASDAQ: ACXP) ($ACXP) interview with David
Luci, President/CEO.
2). Business Capital Firm - Coastal Kapital,
LLC's interview with Kortney Murray, CEO/Founder.
3). ETF Fund - American Conservative Values
ETF's (NYSE: ACVF) ($ACVF) interview with Bill Flaig,
CEO/Founder.
4). Pet Health - PetVivo Holdings, Inc.'s (NASDAQ:
PETV) (NASDAQ: PETVW) ($PETV) interview with John Lai,
CEO/President.
5). "Sekur Privacy & Sekur Security –
Weekly Hack Segment" interview with internet privacy
expert Mr. Alain Ghiai, CEO, Sekur Private Data, Ltd. (OTCQX:
SWISF) (CSE: SKUR) (FRA: GDT0) (Sekur®).
Episode 533
From the Nasdaq MarketSite Studio, New to The
Street's TV Host Jane King talks with David Luci, the President/CEO
of Acurx Phamaceuticals, Inc. (NASDAQ: ACXP) ($ACXP). As a
clinical-stage biopharmaceutical business, ACXP is developing a new
class of antibiotics for life-threatening bacterial infections.
David updates viewers on the Company's FDA Phase 2 clinical trial
on the Ibezapolstat drug, a treatment for patients with
Clostridioides difficile Infections (CDI). Based on positive data
from Phase 2a and Phase 2b, management is now going forward with
the FDA Phase 3. The Company compared its top-line data with the
currently used standard-of-care drugs in the marketplace, and
Ibezapolstat has impressive positive results. Phases 2a and 2b
confirmed that the drug had success in 25 out of 26 patients,
approximately 96% success with no reinfections. Competitor drugs
have been used for decades to treat CDI, but the reinfection rates
are very high. ACXP's Ibezapolsat study results have shown to
combat reinfections effectively. Based on the data and other
publications regarding the market size for newly discovered and
effective treatment of CDI, ACXP believes Ibezapolstat could be a
market worth over $1B. David explains how the Company will fund its
FDA Phase 3 study and, upon successful approval, will leverage
data/results for future approval(s) with the European Medicines
Agency. Decades-old antibacterial drugs are not working due to
changes in the molecular composition of CDI. Thousands of people
worldwide die annually, with many catching CDI in hospitals and
nursing homes. Acurx Pharmaceuticals, Inc. believes its
Ibezapolstat drug is the next generation for effectively treating
CDI. The on-screen QR code is available during the show; download
or visit Acurx Pharmaceticals, Inc. -
https://www.acurxpharma.com/.
From the New York Stock Exchange Studio, New
to The Street's TV Host Jane King is with Kortney Murray,
CEO/Founder of Coastal Kapital, LLC ("Coastal"), a non-bank
and non-credit report funding entity. Capital is the lifeblood of
any business, but many small to mid-size companies cannot secure a
capital line for their operational needs. Kortney started Coastal
Kapital in 2007 to help many secure needed operational funds.
Coastal changed the narrative on funding with Kortney and her team
looking beyond a person's credit score. They examine the business
operations and products/services and perform due diligence to
understand business owners' commitment and sacrifices. Kortney says
that current bank loan algorithms have been in place since the
1950s, and they only look at credit scores as the mathematical
stats to approve loans. Coastal differentiates itself by looking at
the human element behind an operation and seeks to understand the
business owners' needs and how funding can grow existing
operations. Coastal Kapital is raising money through a "Private
Placement Memorandum" under the US SEC Rule 506(c) of Regulation D.
Funds raised will increase the capital pool Coastal can use to
assist those in need. The money raised will help women, minorities,
and other businesses in their operations. Education is key to
financial literacy, and Coastal looks to establish online resources
and other collaborations to help people understand finance
terminologies and methodologies. With current interest rates,
Korney assists many manufacturers and vendors with difficulties
securing necessary equipment and provides sales training and
marketing ideas to grow product sales/services during these
economic times. Throughout 2024, Kortney believes its debt funding
will be in place so Coastal Kapital can expand its reach and help
as many as possible secure business capital needs. Coastal Kapital,
LLC continues to grow regardless of current macroeconomic
conditions, and its services are available nationwide
– "Financing You Can Trust." The on-screen QR code is
available during the show; download or visit Coastal Kapital,
LLC - https://coastalkapital.com/.
American Conservative Values ETF's (NYSE:
ACVF) Bill Flaig, Founder/CEO, and New to The Street's Jane
King are at the New York Stock Exchange Studio talking about the
Fund's conservative investment criteria. The Fund looks for
investments in conservative-run companies seeking growth for its
politically conservative investors. Bill explains that many
investors don't realize that their 401(k) and other investment
instruments have financial positions in public companies whose
management teams are more involved with political ideologies than
running a business effectively. Management with political agendas
hurt shareholder returns and tarnish the brands of goods and
services produced. Unknowingly, an investor's money might be within
investment funds with companies who restrict and promote negativity
on conservative attitudes, promoting it on social media platforms,
reducing banking access, and even denying goods/services to
conservatives. After 25 years in the mutual fund business, Bill and
his partner decided to start ACVF as an investment vehicle to
capitalize on entities not taking a political stance and talking
politics. The Fund's management wants to improve bottom-line
earnings and fiduciary growth for their conservative investors.
ACVF is a proper conservative investment ETF that slightly beats
the S&P in percentage gains and recently received a Morning
Star "4-Star" rating. Bill and his team boycotted many companies
that were hostile to conservative values. ACVF's managers strongly
believe the economic tool of denying companies capital is a
powerful motivation for management to change course and focus on
business, not political policies. The ETF has diversified large-cap
positions to provide large-cap performance and risk management
without woke ideologies. Investment Thesis: "American Conservative
Values ETF (NYSE: ACVF) is based on the conviction that
politically active companies negatively impact their shareholder
returns, as well as support issues and causes opposed to
conservative political ideals, beliefs, and values." Anyone wanting
to learn more can visit the ACVF
website: https://acvetfs.com/. Investors cannot make a stock
position directly with the fund, and all investments need to
facilitate themselves through a brokerage account. The on-screen QR
code is available during the show; download or visit American
Conservative Values ETF (NYSE: ACVF) - https://acvetfs.com/.
(Disclaimer: The Fund is
structured as an ETF and, as a
result, is subject to special risk. Information contained herewith
is not an offer to buy/sell the
stated Fund;
always seek the advice of an investment representative
prior to an investment decision.
Ridgeline Research, LLC is the
adviser for the
Fund).
New to The Street's TV Host Jane King, from the
Nasdaq MarketSite Studio, talks about PetVivo Holdings,
Inc. (NASDAQ: PETV) (NASDAQ: PETVW) ($PETV) ("PetVivo") with
John Lai, CEO/President. PetVivo's patented product, Spryng
with OsteoCushion Technology, gives veterinarians a tool to help
pet owners manage their pets' osteoarthritis and other
joint-related ailments. John informs viewers that the Company is at
New York's Javits Convention Center for the 2023 United States Vet
Show. The attending veterinarians and other animal health
professionals at the show give PETV a platform to educate health
providers on the benefits of using Spryng as a treatment for dogs,
cats, and horses with osteoarthritis. At the Vet Show, a couple of
doctors discussed the clinical results of numerous studies showing
the efficacy and safety of using Spryng. One study revealed the
product as an excellent, non-invasive, non-surgical alternative in
treating dogs with ruptured cranial cruciate ligaments - like ACL
injuries in humans. PETV will be at the American Association
of Equine Practitioners (AAEP) conference in San Diego, California,
and two veterinarians will present the Spryng results and use them
on horses. In January 2024, the Company will be at the Veterinary
Meeting & Expo (VMX) conference in Orlando, Florida. Doctors
will present results and data on Company's Spryng product in this
small animal vet show. John feels these conferences are important
in getting veterinarians and others knowledgeable about published
results, data, and real-life successes on animals treated with
Spryng. They can educate many that the 30-year treatments currently
used can be replaced and improved upon using Spryng. The on-screen
QR code is available during the show; download or visit PetVivo
Holdings, Inc. - https://petvivo.com/ & Spryng with
OsteoCushion Technology - https://www.sprynghealth.com/.
New to the Street TV airs its "Sekur
Privacy & Sekur Security Segment – Weekly
Hack" with internationally acclaimed
internet privacy expert Mr. Alain Ghiai, CEO of Sekur Private Data,
Ltd. (OTCQX: SWISF) (CSE: SKUR) (FRA: GDT0) (Sekur®) and TV
Co-Host / Multi-media Journalist Ana Berry. The "Weekly Hack" is
about ICBC (Industrial and Commercial Bank of China Limited), the
largest bank in the world, getting hacked. Its subsidiary, ICBC
Financial Services (FS), experienced an outage from the ransomware
attack, resulting in a system shutdown. FS' US Government Bond
trades and other financial transactions worth around $9B couldn't
settle, causing a ripple in the financial markets. Alain believes
the bank's corporate email system became compromised, and the
ransomware hack entered their computer system. Alain found it odd
that executives converted to their Gmail accounts to communicate
with clients and others within the organization when the corporate
system was offline. Anytime anyone uses an open-platform, free Big
Tech email, one takes a chance at a cybersecurity breach.
Interestingly, Alain explains to viewers that the Sekur started 10
years ago with the development of a full-server backup product. The
idea came shortly after the Sony Pictures Entertainment hack. Since
then, Sekur has launched several subscription-based products for
individuals and businesses. SekurMail with the SekurSend/SekurReply
feature can greatly eliminate the chances of a cyber breach. An
end-user sends an email from their SekurMail account, the recipient
gets an invitation to proceed, and the whole communication occurs
on Sekur's wholly-owned servers. The email feature can even protect
the recipient who is not a Sekur subscriber. The Company never uses
third-party platforms or software; all product offerings are
encrypted and closed-looped. Another essential solution is
SekurVPN, which offers a Swiss VPN IP address, allowing end-users
to appear always in Switzerland. SekurVPN virtually eliminates the
tracking of end-users' web traffic. All subscribers' electronic
communications are through the Company's owned and maintained data
servers in Switzerland, a country with the strictest privacy laws
in the world. Alain offers viewers who want to subscribe to Sekur
PROMO CODE: PRIVACY, a 15% savings for the next 5
years on all products and bundled services.
Remember: Sekur never sells data, asks for phone
numbers, has no 3rd party cloud applications, and never tracks web
traffic. Viewers, please tune in next week for the "Sekur
Privacy & Sekur Security Segment – Weekly
Hack." The on-screen QR code is available
during the shows to download more info or visit Sekur Private Data,
Ltd. – https://sekurprivatedata.com/, http:/sekur.com/ and
https://sekurvpn.com/. Privacy has arrived!
About Acurx Pharmaceuticals, Inc.
(NASDAQ: ACXP) ($ACXP):
Acurx Pharmaceuticals, Inc. (NASDAQ:
ACXP) ($ACXP) is a clinical-stage
biopharmaceutical Company focused on developing new
antibiotics for difficult-to-treat infections. The Company's
approach is to develop antibiotic candidates that target the DNA
polymerase IIIC enzyme. Its R&D pipeline includes antibiotic
product candidates that target Gram-positive bacteria, including
Clostridioides difficile, methicillin-resistant Staphylococcus
aureus (MRSA), vancomycin-resistant Enterococcus (VRE), and
drug-resistant Streptococcus pneumoniae (DRSP). The Company's
Ibezapolstat is a novel, orally administered antibiotic developed
as a Gram-Positive Selective Spectrum (GPSS™) antibacterial. It is
the first of a new class of DNA polymerase IIIC inhibitors under
development by Acurx to treat bacterial infections. Ibezapolstat's
unique spectrum of activity, which includes C.
difficile but spares other Firmicutes and the important
Actinobacteria phyla, appears to contribute to maintaining a
healthy gut microbiome. The Company completed Phase 2 clinical
trials of Ibezapolstat. To learn more about Acurx
Pharmaceuticals and its product pipeline, please
visit www.acurxpharma.com.
About Coastal
Kapital, LLC:
Coastal Kapital, LLC provides businesses with
the capital needed to get a competitive edge, maximizing a
company's profits. Helping companies succeed since 2007, Coastal
Kapital account executives have over 14 years of experience and
relationships with over 150 different programs. Their clients
understand that time equals money, and Coastal Kapital is the
one-stop shop for all your financial needs and offers its clients
the most innovative programs. They offer equipment leasing,
business loans, working capital, merchant Processing, collateral
assets, and real estate-backed funding, regardless of credit type.
Coastal Kapital is a dedicated financial service leader in
commercial equipment and asset-based lending and maintains
relationships with business owners, vendors, and manufacturers
across the US who value partnerships as well as integrity
- https://coastalkapital.com/.
About American
Conservative Values ETF (NYSE: ACVF):
American Conservative Values ETF (NYSE: ACVF) is
the first ETF for ideologically Conservative investors. The Fund's
goal is to limit the financial impact of executives' political
speech and roll back corporate initiatives that push environmental,
social, and governance (ESG) policies. ACVF is actively managed and
seeks to boycott ownership of companies
which the Adviser determines as hostile to conservative values.
ACVF's shareholder proposals seek to target corporate
initiatives that appear to prioritize activities beyond the
interests of the shareholders. The ETF's portfolio is expected to
be broadly diversified with exposure to growth and value as well as
to all economic sectors. The ETF seeks to manage active risk to
benchmarks such as the Russell 1000 and S&P 500. ACVF is
designed to replace an investor's current large-cap index ETFs and
mutual funds with a conservative alternative –
https://acvetfs.com/. (Disclaimer: The Fund is structured
as an ETF and, as a result, is subject to special risk. Information
contained herewith is not an offer to buy/sell the stated Fund;
always seek the advice of an investment representative before an
investment decision. Ridgeline Research,
LLC is the adviser for the Fund).
About PetVivo Holdings,
Inc. (NASDAQ: PETV) (NASDAQ: PETVW)
($PETV):
PetVivo Holdings, Inc. (NASDAQ: PETV) (NASDAQ:
PETVW) ($PETV) is an emerging biomedical device company currently
focused on the manufacturing, commercialization, and licensing of
innovative medical devices and therapeutics for companion animals.
The Company's strategy is to leverage human therapies for treating
companion animals in a capital and time-efficient way. A key
component of this strategy is the accelerated timeline to revenues
for veterinary medical devices, which enter the market much earlier
than more stringently regulated pharmaceuticals and biologics.
PetVivo has a pipeline of seventeen products for treating animals
and people. A portfolio of nineteen patents protects the Company's
biomaterials, products, production processes, and use methods. The
Company's lead product, Spryng™ with
OsteoCushion™ technology, a veterinarian-administered,
intraarticular injection for managing lameness and other
joint-related afflictions, including osteoarthritis, in dogs and
horses, is currently available for commercial sale -
https://petvivo.com/ and https://www.sprynghealth.com/.
About Sekur Private Data
Ltd. (OTCQX: SWISF) (CSE: SKUR) (FRA: GDT0)
($SWISF):
Sekur Private Data, Ltd. (OTCQX: SWISF) (CSE:
SKUR) (FRA: GDT0) ($SWISF) is a cybersecurity and internet privacy
provider of Swiss-hosted solutions for secure communications and
secure data management. The Company distributes a suite of secure
cloud-based storage, disaster recovery, document management,
encrypted emails, and secure communication tools. It sells its
products through its websites, www.sekur.com, approved
distributors, and telecommunication companies worldwide. Sekur
Private Data, Ltd. serves consumers, businesses, and governments
worldwide -
https:/sekurprivatedata.com and https://sekur.com;
Twitter: @sekurprivate.
About New to The
Street:
New to The Street is an FMW Media production that
operates one of the longest-running US and International sponsored
and syndicated Nielsen-rated programming television brands, "New to
The Street". Since 2009, New to The Street has run biographical
interview segment shows across major U.S. television networks. The
Nielsen-rated and sponsored broadcast programming platform reaches
millions of homes in the US and international markets. FMW's New to
The Street show appears on Bloomberg and the FOX Business Network
as sponsored programming. FMW is also one of the nation's largest
buyers of linear television, long and short-form paid programming -
https://www.newtothestreet.com/.
Forward-Looking Statements Disclaimer
US/Canada:
This press release contains forward-looking
statements within Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934. In
some cases, you can identify forward-looking statements by the
following words: "anticipate," "believe," "continue," "could,"
"estimate," "expect," "intend," "may," "ongoing," "plan,"
"potential," "predict," "project," "should," "will," "would," or
the negative of these terms or other comparable terminology.
However, not all forward-looking statements contain these words.
Forward-looking statements do not guarantee future performance or
results and will not necessarily be accurate indications of when
such performance or results are achieved. This press release should
be considered in all filings of the Companies contained in the
Edgar Archives of the Securities and Exchange Commission at
www.sec.gov.
This press release contains forward-looking
information within the meaning of applicable Canadian securities
laws. Forward-looking information is often, but not always,
identified by the use of words such as "seek," "anticipate,"
"believe," "plan," "estimate," "expect," "likely," and "intend" and
statements that an event or result "may," "will," "should," "could"
or "might" occur or be achieved and other similar expressions.
These statements reflect management's current beliefs and are based
on information currently available to management as of the date
hereof. Forward-looking information in this press release includes,
without limiting, the foregoing expectations. Neither TSX Venture
Exchange nor its Regulation Services Provider (as that term is
defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.
CONTACT:
FMW Media Contact: Monica Brennan
monica@NewtoTheStreet.com 1-917-330-2564
"New to The Street" Business Development Office
1-516-696-5900 Support@NewToTheStreet.com
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/5fca1532-e9e5-4cbc-bf9d-4bbb99c0c31c
Acurx Pharmaceuticals (NASDAQ:ACXP)
Historical Stock Chart
Von Okt 2024 bis Nov 2024
Acurx Pharmaceuticals (NASDAQ:ACXP)
Historical Stock Chart
Von Nov 2023 bis Nov 2024